Lumos Diagnostics Holdings (ASX:LDX) Moat Score: 2/10 (As of Jul. 01, 2026)


ASX:LDX Lumos Diagnostics Holdings Ltd ASX:LDX
31 GF Score
Price A$0.11
GF Value A$0.02
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Lumos Diagnostics Holdings Moat Score?

Lumos Diagnostics Holdings ASX:LDX 31 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates ASX:LDX with a GF Score™ of 31/100 and a GF Value™ of A$0.02 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Lumos Diagnostics Holdings ranks better than 68.2% on this metric.

Lumos Diagnostics Holdings has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Lumos Diagnostics Holdings has No Moat: Lumos Diagnostics has limited market leadership and lacks significant customer switching costs or strong brand loyalty. The company does not possess notable intellectual property or durable cost advantages, and its market presence is not substantial enough to create significant barriers to entry.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Lumos Diagnostics Holdings might have No Moat - Very weak/transient advantages.

Lumos Diagnostics Holdings  (ASX:LDX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Lumos Diagnostics Holdings Moat Score Related Terms

ASX:LDX vs ABT, SYK, MDT: Moat Score Comparison

For the Medical Devices subindustry, Lumos Diagnostics Holdings's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lumos Diagnostics Holdings Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lumos Diagnostics Holdings's Moat Score distribution charts can be found below:

* The bar in red indicates where Lumos Diagnostics Holdings's Moat Score falls into.


ASX:LDX
31GF Score
Lumos Diagnostics Holdings Ltd ASX:LDX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Lumos Diagnostics Holdings (ASX:LDX) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Lumos Diagnostics Holdings ranks #269 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 31.8%.
Is Lumos Diagnostics Holdings' Moat Score too high?
Lumos Diagnostics Holdings' current Moat Score is 2. Based on the distribution chart, Lumos Diagnostics Holdings ranks #269 out of 846 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Lumos Diagnostics Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumos Diagnostics Holdings' Moat Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Lumos Diagnostics Holdings ranks #269 out of 846 companies for Moat Score. This puts Lumos Diagnostics Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Lumos Diagnostics Holdings's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumos Diagnostics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Lumos Diagnostics Holdings (ASX:LDX) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.11 — trading 425% above its estimated fair value. The current Moat Score is 2. Lumos Diagnostics Holdings' overall GF Score™ is 31/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Lumos Diagnostics Holdings (ASX:LDX), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lumos Diagnostics Holdings (ASX:LDX) Overvalued in 2026?

Based on GuruFocus' analysis, Lumos Diagnostics Holdings stock appears to be overvalued. The current stock price of A$0.11 is trading 425% above its estimated GF Value™ of A$0.02. GuruFocus considers Lumos Diagnostics Holdings to be Significantly Overvalued.

Key valuation signals for ASX:LDX:

  • Moat Score: 2
  • GF Value™: A$0.02 vs. price of A$0.11 (425% above fair value)
  • GF Score™: 31/100 with 7 warning signs

No single metric tells the full story. See the ASX:LDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lumos Diagnostics Holdings Business Description

Other Exchanges LDXHF:USA
Address 2724 Loker Avenue West, Carlsbad, CA, USA, 92010
Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture, and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. The group is dedicated to providing contract research and development services, focusing on the innovation, development, manufacturing, and commercialization of point-of-care diagnostic solutions for both clinical and consumer applications. It generates maximum revenue from commercial services and solutions relating to POC diagnostic tests. The group has one operating segment, which is the provision of point-of-care diagnostics goods and services. The Company operates in two geographical regions, the United States and Australia and the majority of revenue is generated from the United States.
31GF Score

Get the complete analysis for ASX:LDX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.11
Price
A$0.02
GF Value